肝细胞癌
队列
医学
接收机工作特性
放射科
内科学
作者
Rex Wan‐Hin Hui,K.W. Chiu,I-Cheng Lee,Chenlu Wang,Ho Ming Cheng,Jian‐Liang Lu,Xianhua Mao,Sarah N. Yu,Lok-Ka Lam,Lung‐Yi Mak,Tan To Cheung,Nam-Hung Chia,Chin‐Cheung Cheung,W. Kan,Tiffany Wong,Albert Chan,Yi‐Hsiang Huang,Man‐Fung Yuen,Philip L. H. Yu,Wai‐Kay Seto
出处
期刊:Hepatology
[Wiley]
日期:2024-12-02
卷期号:82 (2): 344-356
被引量:9
标识
DOI:10.1097/hep.0000000000001180
摘要
Background and Aims: HCC recurrence frequently occurs after curative surgery. Histological microvascular invasion (MVI) predicts recurrence but cannot provide preoperative prognostication, whereas clinical prediction scores have variable performances. Approach and Results: Recurr-NET, a multimodal multiphasic residual-network random survival forest deep-learning model incorporating preoperative CT and clinical parameters, was developed to predict HCC recurrence. Preoperative triphasic CT scans were retrieved from patients with resected histology-confirmed HCC from 4 centers in Hong Kong (internal cohort). The internal cohort was randomly divided in an 8:2 ratio into training and internal validation. External testing was performed in an independent cohort from Taiwan. Among 1231 patients (age 62.4y, 83.1% male, 86.8% viral hepatitis, and median follow-up 65.1mo), cumulative HCC recurrence rates at years 2 and 5 were 41.8% and 56.4%, respectively. Recurr-NET achieved excellent accuracy in predicting recurrence from years 1 to 5 (internal cohort AUROC 0.770–0.857; external AUROC 0.758–0.798), significantly outperforming MVI (internal AUROC 0.518–0.590; external AUROC 0.557–0.615) and multiple clinical risk scores (ERASL-PRE, ERASL-POST, DFT, and Shim scores) (internal AUROC 0.523–0.587, external AUROC: 0.524–0.620), respectively (all p < 0.001). Recurr-NET was superior to MVI in stratifying recurrence risks at year 2 (internal: 72.5% vs. 50.0% in MVI; external: 65.3% vs. 46.6% in MVI) and year 5 (internal: 86.4% vs. 62.5% in MVI; external: 81.4% vs. 63.8% in MVI) (all p < 0.001). Recurr-NET was also superior to MVI in stratifying liver-related and all-cause mortality (all p < 0.001). The performance of Recurr-NET remained robust in subgroup analyses. Conclusions: Recurr-NET accurately predicted HCC recurrence, outperforming MVI and clinical prediction scores, highlighting its potential in preoperative prognostication.
科研通智能强力驱动
Strongly Powered by AbleSci AI